Research Article

Nouman Rasool*, Aisha Ashraf, Muneeba Waseem, Waqar Hussain and Sajid Mahmood

Computational exploration of antiviral activity of phytochemicals against NS2B/NS3 proteases from dengue virus

Dang Virüs'den NS2B/NS3 proteazlarına karşı fitokimyasalların antiviral aktivitesinin hesaplamalı olarak araştırılması

<https://doi.org/10.1515/tjb-2018-0002>

Received May 22, 2017; accepted April 3, 2018; previously published online June 12, 2018

Abstract

Background: Dengue fever has emerged as a serious threat in Pakistan in the last few years with high morbidity rates and substantial mortality. In the present study, NS2B/NS3 protease from four dengue virus (DENV) serotypes have been targeted using 2350 phytochemicals from various medicinal plants.

Material and methods: The phytochemicals were subjected to docking against NS2B/NS3 proteases using AutoDock Vina focusing the binding site, and the binding energies were determined to screen the effectively docked phytochemicals. Pharmacological properties were also analyzed for all the phytochemicals using PreADMET web server.

***Corresponding author: Dr. Nouman Rasool**, Department of Life Sciences, University of Management and Technology, C-II Johar Town, Lahore 54770, Pakistan; and Dr Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan, Phone: +92-307-4449017, e-mail: nouman.rasool@umt.edu.pk. <https://orcid.org/0000-0003-0210-5845>

Aisha Ashraf and Muneeba Waseem: Department of Life Sciences, University of Management and Technology, Lahore, Pakistan, e-mail: 14001231007@umt.edu.pk (A. Ashraf); 14001231001@umt.edu.pk (M. Waseem)

Waqar Hussain: Department of Computer Science, University of Management and Technology, Lahore, Pakistan, e-mail: umt.waqar@outlook.com

Sajid Mahmood: Department of Informatics and Systems, University of Management and Technology, Lahore, Pakistan, e-mail: sajid.mahmood@umt.edu.pk

Results: Binding affinities ranged from -4.0 to -9.8 kcal/mol and a threshold of -9.0 kcal/mol was applied for screening compounds. A total of 18 phytochemicals are screened for passing all evaluation criteria of a drug in which three were for DENV1-NS2B/NS3, five for DENV2-NS2B/NS3, six for DENV3-NS2B/NS3 and four for DENV4-NS2B/NS3. Erycristagallin and Osajin from *Erythrina variegata*, PapraïneA from *Fumaria indica* and Aloe-Emodin from *Aloe vera* are the most potent inhibitors of NS2B/NS3 protease from DENV1, DENV2, DENV3 and DENV4, having binding affinities of -9.6 kcal/mol, -9.6 kcal/mol, -9.6 kcal/mol and -9.2 kcal/mol, respectively.

Conclusion: The effective drug-like properties of all 18 phytochemicals demonstrate the inhibition potential against dengue virus replication in human beings.

Keywords: Dengue virus; NS2B/NS3; Phytochemicals; Molecular docking; ADMET; Virtual screening.

Öz

Amaç: Dang humması, son birkaç yılda yüksek morbidite oranları ve ciddi mortalite ile Pakistan'da ciddi bir tehdit olarak ortaya çıkmıştır. Bu çalışmada, dört dang virüsü (DENV) serotipinden NS2B/NS3 proteazı, çeşitli tıbbi bitkilerden alınan 2350 fitokimyasal kullanılarak hedeflenmiştir.

Gereç ve Yöntemler: Fitokimyasallar, bağlanma alanına odaklanan AutoDock Vina kullanılarak NS2B/NS3 proteazlarına karşı kenetlenmeye tabi tutuldu ve etkin şekilde kenetlenmiş fitokimyasalları taramak için bağlanma enerjileri belirlendi. Farmakolojik özellikler ayrıca PreADMET

web sunucusu kullanılarak tüm fitokimyasallar için analiz edildi.

Bulgular: Bileşikleri taramak için bağlanma afiniteleri -4.0 ila -9.8 kcal/mol arasında ve eşik -9.0 kcal/mol olarak uygulanmıştır. Toplam 18 fitokimyasal bir ilacın tüm değerlendirme kriterlerini geçmesi için tarandı; 3'ü DENV1-NS2B/NS3 için, 5'i DENV2-NS2B/NS3 için, 6'sı DENV3-NS2B/NS3 için ve 4'ü DENV4-NS2B/NS3 içindi. *Erythrina variegata*'den Erycristagallin ve Osajin, *Fumaria indica*'dan PapraïneA ve *Aloe vera*'dan Aloe-Emodin, sırasıyla -9.6 kcal/mol, -9.6 kcal/mol, -9.6 kcal/mol ve -9.2 kcal/mol, bağlanma afiniteleri ile DENV1, DENV2, DENV3 ve DENV4'ten NS2B/NS3 proteazının en güçlü inhibitörleridir.

Sonuç: Tüm 18 fitokimyasal maddenin etkin ilaç benzeri özellikleri, insanlardaki dang virüsü replikasyonuna karşı inhibisyon potansiyelini göstermektedir.

Anahtar Kelimeler: Dang virüsü; NS2B/NS3; Fitokimyasallar; Moleküler kenetlenme; ADMET; Sanal Tarama.

Introduction

Dengue fever is considered to be a very crucial disease with the diagnostic rate of infections of about 2 million people per year across the world. This fever is caused by the dengue virus, belonging to the *Flaviviridae* family. According to the World Health Organization, one-third of the world population is under the dengue virus epidemicity, with a variety of the strains of virus polypeptide [1, 2]. Five serotypes of dengue virus have been identified which are DENV-1, DENV-2, DENV-3 and DENV-4 and DENV-5 [3]. These first four serotypes are closely related in structure, however, they interact differently with the antibodies, present in the human blood serum. These viruses share a similarity of almost 65% in the genome while there are genetic variations within a single serotype. However, these four serotypes cause the same diseases despite having genomic variations. Genome of DENV-5, as compared to the other four serotypes, is less characterized and not much information is present regarding this serotype. The polypeptide of the dengue virus is encoded by a long single-stranded RNA, referred as positive sense RNA, and is further cleaved into ten different proteins (seven non-structural proteins and three structural) [4].

Membrane (M), Envelope (E) and Capsid (C) are the three structural proteins in dengue virus polypeptide whereas seven non-structural proteins are Non-structural protein 1 (NS1), Non-structural protein 2A (NS2A), Non-structural protein 2B (NS2B), Non-structural protein 3 (NS3), Non-structural protein 4A (NS4A), Non-structural

protein 4B (NS4B) and Non-structural protein 5 (NS5) [5, 6]. The process of cleaving the viral precursor polyprotein into different functional proteins is carried out by the aid of viral and host cell proteases. NS3 protein constitutes N-terminal of the serine protease, which helps in cleaving the viral polypeptide into functional proteins. It is reported that NS3 protease has apo behavior and requires NS2B protein, a small protein of 14-kDa, as a cofactor which also stabilizes the NS2B/NS3 complex [7].

Serine proteases are observed to be the most studied proteases among all the four Serine, Aspartic, Metallo and Cysteine classes. The common catalytic apparatus which is Asp, His and Ser, plays a vital role in the conserved mechanism of catalysis among all the serine proteases [8]. The NS2B/NS3 serine protease has a heterodimeric behavior and it cleaves at various positions in the polypeptide of dengue virus such as capsid/membrane, NS2A/NS2B, NS2B/NS3, NS3/NS4A, NS4B/NS5, internal NS2A, NS3, and NS4A cleavage sites [9]. The viral replication is also sustained by this protease. All these functionalities of NS3 mark this protein as an important candidate for drug targeting by inhibiting its function. Various studies have been conducted for the sake of finding a putative and efficient drug candidate against NS2B/NS3 protease, using specific inhibitors and chemical libraries. The protease is reported to be the second largest protein of DENV genome and the conservancy of this protein among the four serotypes is 63–74% [10].

Dengvaxia (CYD-TDV) has been registered as a vaccine against dengue virus after passing through clinical trials. The vaccine is working effectively against seropositive individuals, however, the disease risk is higher in the individuals which are seronegative at the time of vaccination. The main drawback of the drug is the enhanced levels of antibodies, resulting non-protective dengue infection in seronegative patients [11].

It is observed that medicinal plants are being used for the treatment of various diseases since the ancient times. The plant extracts have chemically and biologically active compounds against various diseases. In the present study, NS2B/NS3 protease from four dengue virus serotypes has been targeted using 2350 phytochemicals from various medicinal plants locally present in the Indian Subcontinent. NS2B/NS3 protein of DENV-5 is not yet characterized therefore, it cannot be considered in the present study. Phytochemicals of these plants are used in this study for docking against DENV NS2B/NS3 and their interactions are observed for the discovery of effective drugs. These compounds are further evaluated on the basis of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties. Experimental results show that 18

out of 2350 phytochemicals can be considered as effective drug-like antiviral agents against dengue fever in humans.

Material and methods

The present study targets the NS2B/NS3 protease from four dengue virus serotypes. The crystal structure of these proteases (PDB ID: 3L6P, 2FOM, 3U1I and 2VBC for dengue virus 1, 2, 3 and 4, respectively) were retrieved from RCSB databank [10, 12–14]. For exploring the potential inhibitors against these proteases, 2350 phytochemicals from various plants inhabited in India and Pakistan were searched through the literature survey and downloaded from PubChem. The phytochemical set comprised of 201 alkaloids, 387 terpenoids, 803 flavonoids, 204 isoflavonoids, 362 lignans, 112 isoflavones, 55 anthraquinones, and 226 miscellaneous phytochemicals [15, 16].

Molecular docking and binding energy calculation

The docking study was performed to analyse the inhibition role of phytochemicals against NS2B/NS3 proteases. The ligand and protein preparation was performed in AutoDock Tools while docking was performed using AutoDock Vina [17, 18]. Using the Discovery Studio 2.5 software, water molecules were removed and CHARMM27 force field was applied onto these protein structures. Subsequently, steric overlaps were removed and the structures were processed 1000 steps using the smart-minimizer algorithm [19]. Energy minimization and three-dimensional (3D) structure optimization was carried out for phytochemicals’ structures using ACD ChemSketch [20]. The polar hydrogens were added in all the four receptors and the ligands (phytochemicals) using AutoDock Tools. The polar charges helped to enhance the process of interactions. Torsion adjustment was performed for the ligands as the ligand needs information regarding torsion. This illustrates which torsions are to be treated as rotatable during the docking. The 3D grid was designed to define the search space within receptors, focusing the binding

pocket comprised of catalytic triad residues His, Asp and Ser (Table 1). The interactions of the phytochemicals were analyzed along with the estimation of binding energies using Autodock Vina [8]. Docking simulations were carried out with six different exhaustiveness heuristics i.e. E=4, E=8, E=16, E=32, E=64 and E=128. However, no improvement was observed in terms of binding after the exhaustiveness E=8. The total number of dockings were 9400 (2350*4), performed by utilizing a JAVA based script to automate the docking process. The focused docking approach is reported to have higher accuracy as compared to the blind docking approach [6, 21].

ADMET and drug likeness prediction

Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) of all the compounds were calculated using PreADMET [22]. The program also helped in predicting the drug-likeness of these compounds. The predictions were made using the molecular structure file. Pharmacological properties and pharmacokinetics of the phytochemicals were analyzed using the physically significant descriptors and pharmaceutically relevant properties associated with the ligand molecules.

Results

Molecular docking and binding site prediction

All the four proteases were docked with the 2350 phytochemicals from various local medicinal plants. These phytochemicals interacted differently at the binding pocket, showing various binding affinities ranging from –4.0 to –9.8 kcal/mol. Among all the phytochemicals, 18 phytochemicals (three for DENV1-NS2B/NS3, five for DENV2-NS2B/NS3, six for DENV3-NS2B/NS3 and four for DENV4-NS2B/NS3) were selected on basis of effective drug-like properties and ADMET profiles (Table 2). The docking and binding energies of these selected 18 phytochemicals are discussed in this section.

Table 1: Grid box dimensions for receptors (Å³).

Receptor	Grid box dimensions
DENV1-NS2B/NS3 (PDB ID: 3L6P)	22 × 22 × 30
DENV2-NS2B/NS3 (PDB ID: 2FOM)	18 × 18 × 20
DENV3-NS2B/NS3 (PDB ID: 3U1I)	16 × 18 × 18
DENV4-NS2B/NS3 (PDB ID: 2VBC)	20 × 18 × 18

Docking with DENV1-NS2B/NS3 protease

Oxysanguinarine, an alkaloid from *Fumaria indica*, docked strongly at the binding pocket of DENV1-NS2B/NS3 protease with Glu₂₀, Leu₃₁, Glu₁₄₄, Gln₁₆₀ and Arg₁₉₂ having the binding affinity –9.4 kcal/mol. Papracinine another alkaloid in

Table 2: Structures of screened phytochemicals.

Phytochemicals	Structure
<i>Aloe vera</i> Aloe-Emodin
<i>Fumaria indica</i> Oxysanguinarine
Papracinine
Fumaritine N-oxide

Table 2 (continued)

Phytochemicals	Structure
PapraineA	
PapraineB	
<i>Erythrina variegata</i> Erycristagallin	
Osajin	

Table 2 (continued)

Phytochemicals	Structure
Robustone	
SigmodinB	
SigmodinA	
SigmodinC	

Table 2 (continued)

Phytochemicals	Structure
Abyssinone
EryvarinA
EryvarinB

Table 2 (continued)

Phytochemicals	Structure
EuchrenoneB
Laburnetin
Lupiwighteone

nature from the same plant, docked with the binding affinity of -9.2 kcal/mol. The residues involved in the interactions with Papracinine were Leu₃₁, Gly₁₄₂, Glu₁₄₃ and Gln₁₆₀. Erycristagallin, a pterocarpan from *Erythrina variegata*, was observed to dock effectively with a binding affinity of -9.6 kcal/mol. The residues involved in these interactions were Ile₃₀, Leu₃₁, Ile₄₂, Gln₁₆₀ and Arg₁₉₂ (Table 3).

Docking with DENV2-NS2B/NS3 protease

Fumaritine N-oxide an alkaloid from *F. indica*, docked with the binding affinity -9.2 kcal/mol against DENV-2 serine

protease at His₅₁, Arg₅₄, Val₇₂, Asp₇₅ and Asn₁₅₂. Osajin, a flavonoid from *E. variegata* was docked with the protease, showing highest binding affinity -9.7 kcal/mol among all the phytochemicals. The residues involved in the interaction with the Osajin were Leu₁₂₈, Phe₁₃₀, Pro₁₃₂, Tyr₁₅₀, Gly₁₅₁ and Gly₁₅₃. SigmodinA, another flavonoid from *E. variegata* docked with the protease at His₅₁, Leu₁₂₈ and Pro₁₃₂, having a binding affinity of -9.0 kcal/mol. SigmodinB and SigmodinC, two flavonoids from *E. variegata* docked with the binding affinity of -9.4 kcal/mol. SigmodinB interacted at His₅₁, Asp₇₅, Leu₁₂₈, Pro₁₃₂ and Val₁₅₄ and SigmodinC involved His₅₁, Asp₇₅, Leu₁₂₈, Pro₁₃₂, Ser₁₃₅ and Gly₁₅₃ of the protease (Table 4).

Table 3: Docking results for DENV1-NS2B/NS3.

Phytochemicals	Binding sites (DENV1-NS2B/NS3)	Binding affinities (kcal/mol)
<i>Fumaria indica</i> Oxysanguinarine		-9.4
Papracinine		-9.2
<i>Erythrina variegata</i> Erycristagallin		-9.6

Docking with DENV3-NS2B/NS3 protease

PapraineA and PapraineB, two alkaloids from *F. indica* docked with binding affinity -9.6 kcal/mol. PapraineA interacted with His₅₁, Ser₁₃₅ and Tyr₁₆₁ and PapraineB interacted with His₅₁, Asp₈₁, Gly₁₃₃ and Gly₁₅₁ at the binding site of this protease. The results identified that PaprarineA and PapraineB are potential inhibitors of the DENV3-NS2B/NS3 protease. Robustone from *E. variegata*, being isoflavone in nature, interacted with Val₃₆, His₅₁, Thr₈₃, Mer₈₄ and Pro₁₃₂ with the binding affinity determined was -9.0 kcal/mol. Abyssinone from *E. variegata*, a flavonoid, was docked with the protease having a binding

affinity of -9.4 kcal/mol and established interactions with His₅₁, Thr₈₃, Mer₈₄, Tyr₁₅₀ and Tyr₁₆₁ residues of the binding site. EryvarinA and EryvarinB, two flavonoids from *E. variegata* docked with the binding affinities of -9.0 and -9.3 kcal/mol, respectively. The EryvarinA was docked at His₅₁, Asp₇₅, Asp₈₁, Pro₁₃₂ and Gly₁₅₁ whereas EryvarinB docked at His₅₁, Gly₁₃₃, Tyr₁₅₀, Gly₁₅₃ and Tyr₁₆₁ (Table 5).

Docking with DENV4-NS2B/NS3 protease

Aloe-Emodin, an anthraquinone from the plant *Aloe vera*, docked with His₅₁, Asp₇₅ and Asn₁₅₂ of the binding

Table 4: Docking results for DENV2-NS2B/NS3.

Phytochemicals	Binding sites (DENV2-NS2B/NS3)	Binding affinities (kcal/mol)
<i>Fumaria indica</i> Fumaritine N-oxide		-9.2
<i>Erythrina variegata</i> Osajin		-9.7
SigmodinB		-9.4
SigmodinA		-9.0
SigmodinC		-9.4

Table 5: Docking results for DENV3-NS2B/NS3.

Phytochemicals	Binding sites (DENV3-NS2B/NS3)	Binding affinities (kcal/mol)
<i>Fumaria indica</i> PapraineA		-9.6
PapraineB		-9.6
<i>Erythrina variegata</i> Robustone		-9.0
Abyssinone		-9.4

Table 5 (continued)

Phytochemicals	Binding sites (DENV3-NS2B/NS3)	Binding affinities (kcal/mol)
EryvarinA		−9.0
EryvarinB		−9.3

pocket of DENV4-NS2B/NS3, having a binding affinity of −9.2 kcal/mol. EuchrenoneB, a flavonoid from *E. variegata* docked with the binding affinity of −9.0 kcal/mol with Arg₅₄ and Pro₁₃₂ at the binding site of the protein. Laburnetin and Lupiwighteone, two isoflavones from *E. variegata*, both docked with the binding affinity of −9.1 kcal/mol making interactions with Asn₁₅₂, Ala₁₆₄ and Thr₁₆₆, and Trp₅₀, His₅₁, Arg₇₃ respectively (Table 6).

ADMET and drug likeness prediction

All the successfully docked phytochemicals having the binding affinity −9.0 kcal/mol and above were evaluated for their drug-likeness and ADMET profiles. One of the most effective and important factor to be considered in ADME profiles is the Lipinski's rules non-violations. Physical descriptors such as molecular weight, the hydrogen donor-acceptor bonds and the lipophilicity (logP) of the chemicals are evaluated in these rules. A total of 98 phytochemicals obeyed Lipinski's rules and showed drug like behavior. The Rodent and Ames tests for toxicity prediction helped in further evaluation of these compounds. The results showed that out of these 98 phytochemicals, 53 were non-carcinogenic, non-mutagenic and non-toxic.

These compounds were further evaluated on the basis of blood brain barrier (BBB) penetration behavior. From the 53 compounds, 18 non-penetrating compounds

were observed to be passing BBB evaluation of which six were from *F. indica*, 12 from *E. variegata* and one was from *A. vera* (Table 7). These compounds can be used as potential drugs, having strong inhibitory properties for NS2B/NS3 protein from dengue virus.

Estimated solubility (ESOL) of the phytochemicals from two plants (*A. vera* and *F. indica*) was observed to be high as compared to that of the phytochemicals from *E. variegata*. Erycristagallin, Osajin, SigmodinA, Abysininone and EryvarinB from *E. variegata* showed poor solubility. Gastrointestinal Absorption of all the selected 18 phytochemicals was also high which reflected the effectiveness of these chemicals to be used as drugs.

Discussion

The dengue fever is a pathogenic disease caused by the dengue virus communicated through an insect vector. Virus replication in host cells is carried out by the non-structural proteins. These non-structural proteins are also important for carrying out some other functionalities in host cells. In dengue virus, NS2B/NS3 protease is a trypsin-like serine protease, which plays an important role in cleavage of the polypeptide, transcribed from the viral genome. It is also known to play an important part in viral replication. Due to its multi-functionality, the protease has

Table 6: Docking results for DENV4-NS2B/NS3.

Phytochemicals	Binding sites (DENV4-NS2B/NS3)	Binding affinities (kcal/mol)
<i>Aloe vera</i> Aloe-Emodin		-9.2
<i>Erythrina variegata</i> EuchrenoneB		-9.0
Laburnetin		-9.1
Lupiwighteone		-9.1

always been a target of drug discovery in order to cure the dengue fever. The present study focuses on screening and development of inhibitors of the targeted protease. A total of 2350 phytochemicals from various medicinal plants were docked against the protease. Many studies have been reported focusing the in vitro and in vivo analysis for the

development of drugs against this protease. It is always preferred to perform an in silico analysis before conducting any experimental work, as this kind of analysis is cheap in terms of cost and time consumption.

Triterpenoids phytochemicals from *Azadirachta indica* were evaluated by Dwivedi et al. against NS2B/NS3

Table 7: Pharmacological properties and drug likeness of phytochemicals.

Phytochemicals	Estimated solubility (ESOL)	ESOL class	Gastrointestinal (GI) absorption	Blood-brain barrier (BBB) permeant	Lipinski's rules violations	Rodent test	Ames test	Carcinogenic
<i>Aloe vera</i>								
Aloe-Emodin	-3.04	Soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
<i>Fumaria indica</i>								
Oxysanguinarine	-2.95	Soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
Papracrine	-3.95	Soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
Fumaritine N-oxide	-3.34	Soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
PaprairineA	-4.13	Moderately soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
PaprairineB	-4.13	Moderately soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
<i>Erythrina variegata</i>								
Erycristagallin	-6.58	Poorly soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
Osajin	-6.24	Poorly soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
Robustone	-5.06	Moderately soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
SigmodinB	-4.68	Moderately soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
SigmodinA	-6.22	Poorly soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
SigmodinC	-4.54	Moderately soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
Abyssinone	-6.35	Poorly soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
EryvarinA	-5.2	Moderately soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
EryvarinB	-6.27	Poorly soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
EuchrenoneB	-5.7	Moderately soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
Laburnetin	-4.46	Moderately soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic
Lupiwighteone	-5.11	Moderately soluble	High	No	0	Non toxic	Non toxic	Non carcinogenic

protease and the results of molecular docking showed that nimbin, desacetylnimbin and desacetylsalannin inhibit the NS2B/NS3 protease with the binding affinity -5.56 , -5.24 and -3.43 kcal/mol, respectively. These phytochemicals made interactions with Val₃₆, Arg₇₃, Pro₁₃₂, Gly₁₃₃, Gly₁₅₃ and Val₁₅₄, similar to the results of the present study [23]. Yong et al. targeted the serine protease from dengue virus 3 with the compounds from *Murraya koenigii*. MSC1308 from *M. koenigii* was observed to be a potent inhibitor, making interactions with the Met₈₄, Asp₁₂₉, Phe₁₃₀, Tyr₁₅₀, Asn₁₅₂, Gly₁₅₃, Val₁₅₄, Val₁₅₅, and Tyr₁₆₁ residues with the binding affinity -7.8 kcal/mol [24]. Similarly, in the present study, SigmodinA from *E. variegata* was docked with the protease, showing highest binding affinity -7.8 kcal/mol among all the phytochemicals while making interactions with His₂₃, Ile₃₀, Leu₃₁, Ile₄₂, Gln₁₆₀ and Arg₁₉₂ at the binding pocket. Wu et al. proposed some novel inhibitors against NS2B/NS3 protease from dengue virus 2 and 3 from the diaryl (thio) ethers class. The interactions of these protease inhibitors were observed at catalytic triad residues His₅₁, Asp₇₅, and Ser₁₃₅ of the active site of the protease [25]. In another study, 20 ligands from PubChem/Drug bank were docked against the serine protease from dengue virus 2 which were bound with the various surrounding residues at the binding site [26].

The screened 18 phytochemicals belonged to the three different medicinal plants i.e. five from *F. indica*, 12 from *E. variegata* and one from *A. vera*, all of are found in Pakistan. *Aloe vera* has been used for a long period of time for health, beauty, and skin care purposes, and has potentially active compounds such as amino acids, enzymes, lignin, minerals, salicylic acids, saponins, sugars and vitamins [27]. *Fumaria indica* is an annual herb and is recommended for the treatment of blood disorders, chronic skin diseases, cough, fevers, and urinary diseases [28]. *Erythrina variegata* commonly known as a coral tree and is cultivated due to its ornamental, medicinal, and nitrogen-fixing properties [29]. The phytochemicals from this plant have been used for anti-asthmatic, bacterial infection, cough, febrifuge, fever, helminthiasis, insomnia, inflammation, nervine sedative, cuts and wounds [30]. ADMET of the 18 selected phytochemicals revealed that these compounds have very effective drug like properties along with the non-toxic, non-carcinogenic and non-mutagenic nature. The ADMET was considered as final criteria of screening a huge number of phytochemicals, following various reported techniques [6, 31–33].

Computational approaches for drug discovery and development are proven to be effective and time efficient as they are not based on difficult laborious works. The protein-ligand docking elucidates the mechanism

of inhibition along with the specificity and efficiency of that ligand as an inhibitor. ADMET evaluation helps in computational determination of absorption, distribution, metabolism, excretion and toxicity for use in humans. In silico studies help in identifying selective compounds efficiently and further these compounds can be considered for in vitro analysis because in vitro analysis of a large number of compounds is a time consuming and costly process. It is common practice adopted by researchers to perform computational analysis of compounds for their efficacies against enzymes before going to perform in vitro or in vivo investigations.

The association of drug candidate (ligand) to its target receptor is a fundamental binding reaction and the aim of the computer-aided drug discovery is to find small molecules having strong inhibitory or activating action against the biological targets. The strength of inhibition or activation is elucidated through binding affinity [34]. In the present study, the screened 18 phytochemicals showed high inhibitory potential against the NS2B/NS3 proteases as binding affinities of these compounds is ≥ -9.0 kcal/mol. In a previous study, the inhibitory effect of baicalein and baicalin against DENV Envelope, NS2B-NS3 protease and NS5 protein has been identified using molecular docking approaches by Hassandarvish et al. [35]. Both compounds have shown binding affinities -8.0 kcal/mol and -7.5 kcal/mol, respectively against NS2B-NS3 protease. In vitro analysis revealed that IC₅₀ was $68.65 \mu\text{g mL}^{-1}$ for baicalein and $144 \mu\text{g mL}^{-1}$ for baicalin against NS2B-NS3 protease, elucidating the potential of these two compounds against DENV replication [35]. It is manifested that the screened 18 compounds, in our study, can effectively inhibit in vitro intracellular replication of DENV because these compounds have higher binding affinities (≥ -9.0 kcal/mol) as compared to that of baicalein and baicalin. Makau et al. identified potential inhibitors using in silico and in vitro studies against nucleoprotein from Influenza A virus. A set of 9430 compounds was docked against the protein and the screened compound (NUD-1), belonging to 4-hydroxyquinolinone class, was considered for further in vitro analysis. In vitro analysis revealed the potential of NUD-1 against Influenza A virus as the inhibitory concentration ranged within 1.8 – $2.1 \mu\text{M}$ for NUD-1 [36].

The proposed study focused on identification of potential inhibitors against NS2B/NS3 protease from dengue virus to control the viral replication. After the evaluation of the results, 18 phytochemicals are identified as potent inhibitors against dengue fever. The phytochemicals showed strong inhibition against NS2B/NS3 proteases from four serotypes of DENV. Pharmacological assessment of the compounds revealed the effective drug-likeness and

pharmacokinetics of these phytochemicals to be used against dengue fever and other crucial diseases caused by DENV. Therefore, the effect of these inhibitors can be further elucidated through in vitro and in vivo analysis in the cessation of intracellular replication of dengue virus, prior to the use as drugs in humans.

Conflict of interest statement: The authors declare no conflict of interest.

References

- Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. *Nature* 2013;496:504–7.
- Añez G, Heisey DA, Volkova E, Rios M. Complete genome sequences of dengue virus type 1 to 4 strains used for the development of CBER/FDA RNA reference reagents and WHO International Standard candidates for nucleic acid testing. *Genome Announc* 2016;4:1583–98.
- Mustafa MS, Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus (DENV-5): a new public health dilemma in dengue control. *Med J Armed Forces India* 2015;71:67–70.
- Normile D. Surprising new dengue virus throws a spanner in disease control efforts. *Science* 2013;342:415.
- Endy TP, Anderson KB, Nisalak A, Yoon IK, Green S, Rothman AL, et al. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. *PLoS Negl Trop Dis* 2011;5:e975.
- Qaddir I, Rasool N, Hussain W, Mahmood S. Computer-aided analysis of phytochemicals as potential dengue virus inhibitors based on molecular docking, ADMET and DFT studies. *J Vector Borne Dis* 2017;54:140.
- Messer WB, Gubler DJ, Harris E, Sivananthan K, De Silva AM. Emergence and global spread of a dengue serotype 3, subtype III virus. *Emerg Infect Dis* 2003;9:800–9.
- Murthy HK, Clum S, Padmanabhan R. Dengue virus NS3 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. *J Biol Chem* 2009;284:34468.
- Bera AK, Kuhn RJ, Smith JL. Functional characterization of cis and trans activity of the Flavivirus NS2B-NS3 protease. *J Biol Chem* 2007;282:12883–92.
- Chandramouli S, Joseph JS, Daudenarde S, Gatchalian J, Cornillez-Ty C, Kuhn P. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. *J Virol* 2010;84:3059–67.
- Aguiar M, Stollenwerk N, Halstead SB. The risks behind Dengvaxia recommendation. *Lancet Infect Dis* 2016;16:882.
- Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim SP, et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. *Nat Struct Mol Biol* 2006;13:372–4.
- Noble CG, Seh CC, Chao AT, Shi PY. Ligand-bound structures of the dengue virus protease reveal the active conformation. *J Virol* 2012;86:438–46.
- Luo D, Xu T, Hunke C, Grüber G, Vasudevan SG, Lescar J. Crystal structure of the NS3 protease-helicase from dengue virus. *J Virol* 2008;82:173–83.
- Ashfaq UA, Mumtaz A, ulQamar T, Fatima T. MAPS Database: medicinal plant activities, phytochemical and structural database. *Bioinformation* 2013;9:993.
- Mumtaz A, Ashfaq UA, ulQamar MT, Anwar F, Gulzar F, Ali MA, et al. MPD3: a useful medicinal plants database for drug designing. *Nat Prod Res* 2017;31:1228–36.
- Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J Comput Chem* 2009;30:2785–91.
- Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* 2010;31:455–61.
- Visualizer DS. 2.5. 5, Accelrys Inc. San Diego, 2010.
- ACD/Structure Elucidator, version 15.01, Advanced Chemistry Development, Inc., Toronto, ON, Canada. www.acdlabs.com. 2015.
- Ghera D, Sanchez R. Improving accuracy and efficiency of blind protein-ligand docking by focusing on predicted binding sites. *Proteins StructFunctBioinf* 2009;74:417–24.
- Lee SK, Lee IH, Kim HJ, Chang GS, Chung JE, No KT. The PreADME Approach: Web-based program for rapid prediction of physicochemical, drug absorption and drug-like properties. *EuroQSAR 2002 Designing Drugs and Crop Protectants: processes, problems and solutions*. 2003;2003:418–20.
- Dwivedi VD, Tripathi IP, Mishra SK. *In silico* evaluation of inhibitory potential of triterpenoids from *Azadirachta indica* against therapeutic target of dengue virus, NS2B-NS3 protease. *J Vector Borne Dis* 2016;53:156.
- Yong KS, Choi SB, Wahab HA. Docking of dengue NS2BNS3 protease with Murrayakoenigii. In: 3rd International Conference on Computation for Science and Technology, Bali, Indonesia, 2015:82–4.
- Wu H, Bock S, Snitko M, Berger T, Weidner T, Holloway S, et al. Novel dengue virus NS2B/NS3 protease inhibitors. *Antimicrob Agents Chemother* 2015;59:1100–9.
- Balajee R, Srinivasadesikan V, Sakthivadivel M, Gunasekaran P. In silico screening, alanine mutation, and DFT approaches for identification of NS2B/NS3 protease inhibitors. *Biochem Res Int* 2016;2016:1–13.
- Atherton P. The essential Aloe vera: the actions and the evidence 1997. UK: Mill Enterprises.
- Khare CP. Indian herbal remedies: rational Western therapy, ayurvedic, and other traditional usage, Botany 2004. Berlin, Germany: Springer Science and Business Media.
- Cui L, Thuong PT, Fomum ZT, Oh WK. A new erythrinan alkaloid from the seed of *Erythrina addisoniae*. *Arch Pharm Res* 2009;32:325–8.
- Anwar M. The pharmacognostic and pharmacological studies on medicinal valued herbal drugs, erythrinavariegata var. *Orientalis*, *matricariachamomilla*, *psoraleacorylifolia* and *chenopodium album* 2008. PhD dissertation. Available at: <http://eprints.hec.gov.pk/2687/1/2531.html>.
- Ritter JM. Wiley Handbook of current and emerging drug therapies. *Br J Clin Pharmacol* 2008;65:449.
- Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery—toxicological screening tests. *Int J Mol Sci* 2011;13:427–52.

33. Malik R, Mehta P, Srivastava S, Choudhary BS, Sharma M. Structure-based screening, ADMET profiling, and molecular dynamic studies on mGlu2 receptor for identification of newer antiepileptic agents. *Biomol Struct Dyn* 2016;35:1–16.
34. Yunta MJ. Docking and ligand binding affinity: uses and pitfalls. *Am J Model Optim* 2016;4:74–114.
35. Hassandarvish P, Rothan HA, Rezaei S, Yusof R, Abubakar S, Zandi K. *In silico* study on baicalein and baicalin as inhibitors of dengue virus replication. *RSC Adv* 2016;6:31235–47.
36. Makau JN, Watanabe K, Ishikawa T, Mizuta S, Hamada T, Kobayashi N, et al. Identification of small molecule inhibitors for influenza a virus using *in silico* and *in vitro* approaches. *PLoS One* 2017;12:e0173582.